Interactive Brokers Jumps 41.8% in 3 Months: How to Play the Stock?
Price Performance
Does the Interactive Brokers stock have more upside left despite showing recent strength in share price? Let us try to find out.
What's Aiding IBKR's Performance?
Technological Excellence: Interactive Brokers' technological superiority remains one of its strongest aspects. The company processes trades in stocks, digital assets, futures, options and forex on more than 150 exchanges across several countries and currencies.
IBKR's compensation expense relative to net revenues (10.9% in the first half of 2025) remain below its industry peers due to its superior technology. Further, the company has been emphasizing developing proprietary software to automate broker-dealer functions, leading to a steady rise in revenues. Over the last five years (2019-2024), total net revenues witnessed a compound annual growth rate (CAGR) of 21.8%, with the momentum continuing in the first half of 2025.
Revenue Growth
Given the company's solid Daily Average Revenue Trade (DART) numbers, along with a robust trading backdrop, its net revenues are expected to improve in the quarters ahead.
Global Expansion Through Product Diversification: Interactive Brokers has been undertaking several measures to enhance its global presence. In May 2025, it extended the trading hours for Forecast Contracts to nearly 24 hours a day. In April, it launched the prediction markets hub in Canada to capitalize on the rising demand for event contracts.
In November 2024, IBKR introduced Plan d'Epargne en Actions accounts to boost its offerings for its French clients. Also, the launch of IBKR GlobalTrader has enabled investors worldwide to trade stocks through mobile applications.
IBKR was one of the first brokers to introduce Overnight Trading on U.S. stocks and ETFs nearly 24 hours a day, five days a week. IBKR Lite has enabled investors to trade commission-free. Moreover, the launch of Impact Dashboard, an innovative sustainable investing tool, has made the company the first major brokerage firm to allow investors to easily align their portfolio with their values. IBKR also launched cryptocurrency trading via Paxos Trust Company, charging commissions that are lower than those of other crypto exchanges.
The introduction of IBKR Desktop, the next-generation desktop trading application for Windows and Mac, marks a new chapter for innovation.
Robust Liquidity Position: Interactive Brokers has been consistent with its dividend payments for a long time. In April 2024, the company hiked its quarterly dividend 150% to 25 cents per share, followed by a 28% hike in April 2025. Additionally, it announced a four-for-one forward split of its common stock to make shares more accessible to investors.
As of June 30, 2025, IBKR had cash and cash equivalents (including cash segregated for regulatory purposes) of $49.7 billion. Moreover, the company uses insignificant debt to finance its operations. Thus, given a solid liquidity position, IBKR's capital distribution actions look sustainable.
What's Hurting IBKR's Growth
Elevated Expense Base: Interactive Brokers has been witnessing a steady increase in non-interest expenses over the past few years. Expenses witnessed a CAGR of 13.8% over the five years ended 2024, with the uptrend persisting in the first six months of 2025.
Expense Trend
The increase has been mainly due to higher execution, clearing and distribution fees. As the company continues to invest in franchises, launch new products and services, and upgrade technology, overall costs are likely to remain elevated.
High Reliance on International Revenues: IBKR is a geographically diversified company with a presence across the globe. The company generates a large portion of its revenues (almost 37% of total net revenues) from overseas operations.
Several risks stemming from the regulatory and political environment, foreign exchange fluctuations and the performance of local economies may hurt its financials.
Final Thoughts on IBKR Stock
Interactive Brokers remains well-positioned for growth in the current volatile operating environment. While the company's profitability is expected to be hampered because of elevated expenses, its strong technological capabilities and diversified product offerings enhance its global reach, thus supporting long-term growth.
Also, rapidly evolving trends will benefit the company's revenues and expand its market share.
Over the past 30 days, the Zacks Consensus Estimate for the company's 2025 and 2026 earnings has moved upward. The estimates reflect year-over-year growth rates of 9.7% and 6.7% for 2025 and 2026, respectively.
Earnings Estimates
Image Source: Zacks Investment Research
The upward earnings estimate revisions reflect that analysts are optimistic regarding IBKR's earnings growth potential. Thus, it seems to be a wise idea to invest in the stock now.
At present, IBKR sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Charles Schwab Corporation (SCHW): Free Stock Analysis Report
Interactive Brokers Group, Inc. (IBKR): Free Stock Analysis Report
Tradeweb Markets Inc. (TW): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
ER+/ HER2-VE Breast Cancer Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'ER positive, HER2 negative Breast Cancer Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report In August 2025, Yale University announced a phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Patients with ER+ breast cancer anatomic stage IIB or III at diagnosis who are at least five years from diagnosis and have completed intended course of adjuvant endocrine therapy and are currently off endocrine therapy will be screened with ctDNA testing. In July 2025, Atossa Therapeutics Inc. announced a study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment. The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies Camizestrant: AstraZeneca Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant's ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer. (Z)-endoxifen: Atossa Therapeutics, Inc. (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer. AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg. The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment. ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market. Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs ER+/ HER2 -ve Breast Cancer Companies AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report Coverage- Global ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight's exclusive pipeline Report—access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary ER+/ HER2-VE Breast Cancer: Overview Pipeline Therapeutics Therapeutic Assessment ER positive, HER2 negative Breast Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Camizestrant: AstraZeneca Drug profiles in the detailed report….. Mid Stage Products (Phase II) (Z)-endoxifen: Atossa Therapeutics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) AC699: Accutar Biotechnology Inc Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ER+/ HER2-VE Breast Cancer Key Companies ER+/ HER2-VE Breast Cancer Key Products ER+/ HER2-VE Breast Cancer- Unmet Needs ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion ER+/ HER2-VE Breast Cancer Analyst Views ER+/ HER2-VE Breast Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
31 minutes ago
- Globe and Mail
Townsquare (TSQ) Q2 Revenue Slips 2%
Key Points GAAP revenue edged past analyst estimates at $115.4 million in Q2 2025, though Net revenue (GAAP) declined 2.3% year-over-year. Digital net revenue became a clear majority, while digital growth slowed to 2.1% in Q2 2025, down from stronger recent quarters. Adjusted (Non-GAAP) EPS missed expectations, coming in at $0.22 versus the $0.26 analyst estimate. These 10 stocks could mint the next wave of millionaires › Townsquare Media (NYSE:TSQ), a local media and digital marketing company focused on mid-sized markets, released its second quarter 2025 earnings on August 6, 2025. The company's most notable news: GAAP revenue modestly exceeded Wall Street expectations, reaching $115.4 million compared to the $114.8 million consensus in Q2 2025. Adjusted earnings per diluted share (EPS, Non-GAAP) missed expectations at $0.22, below the $0.26 analyst estimate for Q2 2025. Net income (GAAP) swung strongly positive, moving from a loss in the prior-year period to a $2.0 million gain in Q2 2025—as Digital business accounted for approximately 52% of company revenue and 50% of segment profit in the first half of 2025. The overall quarter showed ongoing digital transformation, resilient profitability, and progress on leverage reduction, but also signs of slower digital growth, as Townsquare's total digital net revenue growth decelerated from +6.4% year-over-year in Q1 2025 to +4.1% for the first six months of 2025 and continued declines in legacy broadcast revenue, with broadcast advertising net revenue decreasing 9.2% year-over-year in Q2 2025 and for the first half of 2025. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS – Diluted (Non-GAAP) $0.22 $0.26 $0.14 57.1 % Revenue (GAAP) $115.4 million $114.8 million $118.2 million (2.3 %) Adjusted EBITDA (Non-GAAP) $26.4 million $26.2 million 0.8 % Net Income (GAAP) $2.0 million $(48.9 million) n/m Digital Net Revenue $61.3 million $60.0 million 2.2 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Profile and Key Strategic Areas Townsquare Media operates as a local media, digital marketing, and radio company, but its strategy has increasingly focused on digital products. It serves markets outside the top 50 largest U.S. cities, providing localized digital content, digital advertising, subscription marketing solutions, and broadcasting. The company positions itself as a 'digital first' business, prioritizing growth in digital advertising (the Ignite platform) and subscription marketing solutions (Townsquare Interactive). Recently, the company has worked to shift its revenue mix, moving digital services ahead of traditional broadcast radio. Success now relies on growing digital revenue, maintaining high engagement with local audiences, and leveraging its advantage in markets with fewer large competitors. The company's competitive position outside major media markets and its focus on local content remain central differentiators. Adhering to Federal Communications Commission (FCC) rules and diversifying revenue across business lines are also vital to operations and stability. Quarter in Review: Notable Developments and Segment Trends Digital net revenue grew 2.1% in Q2 2025, now representing 55% of company-wide net revenue in the first half of 2025. While this marked a slowdown versus recent quarters, the digital share both in revenue and profit underscores the strategic shift that is underway. Digital advertising revenue from the Ignite platform rose 2.4% year-over-year in Q2 2025, down from the 8% pace seen in Q1 2025. Subscription digital marketing solutions, delivered through Townsquare Interactive, registered revenue growth of 1.4% in Q2 2025, alongside a pronounced 15.2% jump in segment profit in Q2 2025. Digital segment profit increased 4.3% year-over-year in Q2 2025, with digital-related activities accounted for 56% of segment profit in the first half of 2025. Digital segment margins stood at 27% in the first half of 2025. However, within digital advertising, profit edged down 1.0% in Q2 2025. These results followed a brief dip in customer demand in April 2025, which management linked to heightened economic uncertainty, which rebounded by the latter half of the quarter. Townsquare Interactive's profitability increased sharply in Q1 2025, attributed to efficiencies and operational changes implemented over the past year. The company's legacy broadcast advertising continued to face headwinds. Broadcast ad revenue fell 9.2% in Q2 2025, with segment profit down 8.4% for broadcast advertising in Q2 2025. Management continues to see radio as a cash-generating—if shrinking—business. The focus outside the top 50 markets appears to help dampen some revenue declines as the company takes share in less contested spaces. Other revenue, such as from live events, surged 19.9% in Q2 2025 (GAAP), representing the fastest growth, but remaining a small share of total sales at roughly $5.5 million in Q2 2025. Progress on capital structure continued in the quarter. Townsquare Media repaid $10 million of debt in Q2 2025 and finished Q2 2025 with $467.1 million in outstanding debt and $3.2 million in cash on hand. Net leverage fell slightly to 4.58 times trailing adjusted EBITDA for the twelve months ended June 30, 2025. It maintained a quarterly dividend of $0.20 per share, consistent with prior quarters. Operating cash flow in the first half of 2025 totaled $10.1 million, slightly lower than a year ago. Capital expenditures for the six months ended June 30, 2025, were $8.3 million. Products and Revenue Breakdown Explained The Ignite platform is Townsquare's digital advertising business, offering programmatic—automated and data-driven—buying across online channels such as search, display ads, social media, and video for local businesses. About 60% of segment digital ad revenue came from programmatic in Q1 2025. The Subscription Digital Marketing Solutions segment, Townsquare Interactive, provides software services to small and medium-sized businesses—such as website design, management tools, and online marketing through monthly subscription fees. Each of these areas is targeted toward improving local client engagement and advertising reach in mid-sized markets. Digital revenue streams have surpassed both the company's traditional broadcast radio advertising and smaller 'other' categories, including local events. In Q1 2025, digital advertising comprised 37.3% of net revenue. Subscription digital marketing made up approximately 16% of net revenue in Q2 2025. Broadcast advertising represented 46.3% of total net revenue for the year ended December 31, 2024, and other lines contributed about 5 %. Looking Ahead: Guidance and Key Watch Areas For Q3 2025, management guided to net revenue of $106.5 million to $108.5 million and Adjusted EBITDA is expected to be between $22.0 million and $23.0 million for Q3 2025. For FY2025, Townsquare Media affirmed its outlook, targeting net revenue of $435 million to $440 million and adjusted EBITDA in the $90 million to $94 million range. Both sets of numbers match or slightly narrow the company's prior guidance for Q2 2025 and the full year, indicating management's measured confidence in current trends and spending patterns. Investors will want to monitor the speed of digital growth, which slowed in Q2 2025 after several periods of faster expansion. The shift could be due to maturation, strong prior-year results, or broader uncertainty in economic conditions affecting advertisers. Additionally, the company's cash balance and ongoing leverage will bear watching, especially as dividend payments continue and if advertising demand fluctuates. Townsquare Media continues to pay a quarterly dividend of $0.20 per share. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025
Globe and Mail
38 minutes ago
- Globe and Mail
Expeditors Appoints David A. Hackett as CFO
Expeditors International of Washington, Inc. (NYSE: EXPD) announced the appointment of David A. Hackett on August 4, 2025, as Senior Vice President and Chief Financial Officer, effective October 1, 2025. Hackett has served as Vice President, Finance, since May 2024. On August 4, 2025, Expeditors' current Senior Vice President and Chief Financial Officer, Bradley S. Powell, notified the Board of Directors of his intention to retire, effective September 30, 2025. These announcements demonstrate the company's commitment to succession planning. 'Dave has fully integrated himself into our finance and accounting operations and fits seamlessly with our culture, having worked closely with Brad to learn our services, business model and strategies since joining Expeditors as Vice President of Finance in May 2024,' said Daniel R. Wall, President and Chief Executive Officer. 'Dave also worked directly with our other executives and the Board and traveled to many Districts throughout our global network to learn our operations at the field level and meet with a great many employees. With his wealth of financial capabilities and demonstrated leadership, we are fully confident in Dave's ability to step in as CFO.' Wall added, 'I can't thank Brad enough for his strong hand in overseeing our financial health and growth. Brad built a strong team around him and managed through some of the most difficult events in our company's history, including the 2008 financial crisis and the COVID-19 pandemic. Through it all, Brad has brought unflappable leadership and strategic thinking to the role of Chief Financial Officer. At least as significantly, Brad brought us his unrelenting focus on investing in our people, profitability, and cash flow. Over the past 17 years under Brad, Expeditors has increased its dividend from $0.32 to $1.54 and has returned a total of $12 billion to shareholders through share repurchases and dividends. We all wish Brad the best in a well-deserved retirement.' Upon his appointment, Hackett commented, 'The Expeditors culture is unique, and I appreciate getting to know so many people throughout the organization. I'm humbled and honored to build on Brad's legacy in leading the finance and accounting function as part of the executive team of this great company. I'm also excited to help shape strategy that drives sustainable, profitable, and capital-efficient growth for our employees and shareholders.' Dave Hackett, 52, joined Expeditors in May 2024 as Vice President, Finance. Prior to Expeditors, Hackett served in many roles across finance at NIKE, Inc. for nearly 16 years, with 7 of these years as a vice president in the finance and strategy function as part of the NIKE Corporate Leadership Team. During his time at NIKE, he led external reporting, was Controller of North America and Vice President of Global Treasury and Financial Risk Management. Prior to NIKE, Hackett spent nearly 9 years in the audit function of KPMG where he was a senior manager and led the audit teams for some of the firm's largest public clients in the Pacific Northwest. He also obtained his CPA certification in the state of Oregon in 1998. Expeditors is a global logistics company headquartered in Bellevue, Washington. The Company employs trained professionals in 172 district offices and numerous branch locations located on six continents linked into a seamless worldwide network through an integrated information management system. Services include the consolidation or forwarding of air and ocean freight, customs brokerage, vendor consolidation, cargo insurance, time-definite transportation, order management, warehousing and distribution and customized logistics solutions.
